Emergent Biosolutions, Inc. (NYSE:EBS) Director George A. Joulwan sold 14,251 shares of Emergent Biosolutions stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $41.24, for a total value of $587,711.24. Following the transaction, the director now directly owns 34,323 shares in the company, valued at approximately $1,415,480.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Emergent Biosolutions, Inc. (NYSE EBS) opened at $40.86 on Friday. The stock has a market capitalization of $1,691.40, a P/E ratio of 21.62, a P/E/G ratio of 1.13 and a beta of 1.22. The company has a current ratio of 7.37, a quick ratio of 6.46 and a debt-to-equity ratio of 0.38. Emergent Biosolutions, Inc. has a 1 year low of $25.96 and a 1 year high of $44.86.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. The business had revenue of $149.43 million for the quarter, compared to analysts’ expectations of $124.55 million. During the same quarter in the previous year, the firm earned $0.56 earnings per share. The business’s revenue was up 4.6% on a year-over-year basis. research analysts forecast that Emergent Biosolutions, Inc. will post 1.64 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Emergent Biosolutions, Inc. (EBS) Director Sells $587,711.24 in Stock” was reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.watchlistnews.com/emergent-biosolutions-inc-ebs-director-sells-587711-24-in-stock/1697457.html.

A number of hedge funds have recently bought and sold shares of EBS. Riverhead Capital Management LLC boosted its position in Emergent Biosolutions by 102.8% in the second quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 1,542 shares during the last quarter. Ameritas Investment Partners Inc. boosted its position in Emergent Biosolutions by 23.2% in the second quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 587 shares during the last quarter. Creative Planning boosted its position in Emergent Biosolutions by 1.2% in the second quarter. Creative Planning now owns 4,555 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 55 shares during the last quarter. First Quadrant L P CA purchased a new position in Emergent Biosolutions in the third quarter worth $157,000. Finally, Meeder Asset Management Inc. boosted its position in Emergent Biosolutions by 94.7% in the third quarter. Meeder Asset Management Inc. now owns 4,732 shares of the biopharmaceutical company’s stock worth $191,000 after purchasing an additional 2,302 shares during the last quarter. 85.98% of the stock is currently owned by institutional investors and hedge funds.

EBS has been the topic of several analyst reports. BidaskClub cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Zacks Investment Research raised Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a research report on Wednesday, October 25th. Finally, Wells Fargo & Company reaffirmed an “outperform” rating and set a $43.00 target price (up previously from $41.00) on shares of Emergent Biosolutions in a research report on Saturday, September 30th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $45.00.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.